Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients

被引:1
|
作者
Tortosa-Carreres, Jordi [1 ,2 ,3 ]
Cubas-Nunez, Laura [3 ]
Quiroga-Varela, Ana [4 ,5 ]
Castillo-Villalba, Jessica [3 ,4 ,5 ]
Ramio-Torrenta, Lluis [4 ,5 ,6 ,7 ]
Piqueras, Monica [1 ,2 ,8 ]
Gasque-Rubio, Raquel [2 ,3 ]
Quintanilla-Bordas, Carlos [3 ,9 ]
Sanz, Maria Teresa [10 ]
Lucas, Celia [11 ]
Huertas-Pons, Joana Maria [4 ,5 ]
Miguela, Albert [4 ,5 ]
Casanova, Bonaventura [3 ,9 ]
Laiz-Marro, Begona [1 ]
Perez-Miralles, Francisco Carlos [3 ,9 ]
机构
[1] La Fe Univ & Polytech Hosp, Lab Dept, Valencia 46026, Spain
[2] Univ Valencia, Med Dept, Valencia 46010, Spain
[3] Hlth Res Inst La Fe IISLAFE, Neuroimmunol Unit, Valencia, Spain
[4] Dr Josep Trueta Univ Hosp, Neurol Dept, Girona Neuroimmumol & Multiple Sclerosis Unit, Girona, Spain
[5] Santa Caterina Hosp, Girona, Spain
[6] Girona Biomed Res Inst IDIBGI, Neurodegenerat & Neuroinflammat Res Grp, Girona, Spain
[7] Univ Girona, Med Sci Dept, Girona, Spain
[8] Hlth Res Inst La Fe IISLAFE, Resp Infect, Valencia, Spain
[9] La Fe Univ & Polytech Hosp, Neurol Dept, Valencia 46026, Spain
[10] Univ Valencia, Dept Didact Math, Valencia, Spain
[11] La Fe Univ & Polytech Hosp, Comp Syst, Valencia 46026, Spain
关键词
Multiple sclerosis; Prognosis; Free kappa light chains; Therapeutic failure;
D O I
10.1016/j.msard.2024.105734
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Our objective was to explore various biomarkers for predicting suboptimal responses to diseasemodifying treatments (DMTs) in patients with MS (pwMS).<br /> Methods: We conducted a longitudinal, bicentric study with pwMS stratified based on their DMTs responses. Treatment failure (TF) was defined as the onset of a second relapse, presence of two or more T2 new lesions, or disability progression independent of relapse during the follow-up period. We evaluated intrathecal synthesis (ITS) of IgG and IgM using OCB, linear indices, and Reibergrams. Free kappa light chains ITS was assessed using the linear index (FKLCi). NfL and GFAP in serum and CSF, and CHI3L1 in CSF were quantified. Quantitative variables were dichotomized based on the third quartile. Predictive efficacy was assessed through bivariate and multivariate analyses, adjusting for age, sex, EDSS, acute inflammatory activity (AI) -defined as the onset of a relapse or gadolinium-enhancing lesions within a 90-day window of lumbar puncture-, treatment modality, study center, and time from disease onset to treatment initiation. In case of collinearity, multiple models were generated or confounding variables were excluded if collinearity existed between them and the biomarker. The same methodology was used to investigate the predictive potential of various combinations of two biomarkers, based on whether any of them tested positive or exceeded the third quartile.<br /> Results: A total of 137 pwMS were included. FKLCi showed no differences based on AI, no correlation with EDSS and was significantly higher in pwMS with TF (p = 0.008). FKLCi>130 was associated with TF in bivariate analysis (Log-Rank p = 0.004). Due to collinearity between age and EDSS, two different models were generated with each of them and the rest of the confounding variables, in which FKLCi>130 showed a Hazard Ratio (HR) of 2.69 (CI: 1.35-5.4) and 2.67 (CI: 1.32-5.4), respectively. The combination of either FKLC or sNfL exceeding the third quartile was also significant in bivariate (Log-Rank p = 0.04) and multivariate (HR=3.1 (CI: 1.5-6.5)) analyses. However, when analyzed independently, sNfL did not show significance, and FKLCi mirrored the pattern obtained in the previous model (HR: 3.04; CI: 1.51-6.1). Treatment with highefficacy DMTs emerged as a protective factor in all models.<br /> Discussion: Our analysis and the fact that FKLCi is independent of EDSS and AI suggest that it might be a valuable parameter for discriminating aggressive phenotypes. We propose implementing high-efficacy drugs in pwMS with elevated FKLCi.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis: Relationship with disease course and activity
    Kosehasanogullari, Gorkem
    Ozakbas, Serkan
    Tufan, Serap
    Kaya, Derya
    Idiman, Egemen
    NEUROLOGY, 2008, 70 (11) : A381 - A381
  • [42] Cerebrospinal Fluid IgA Levels Correlate with Disease Activity in Patients with Multiple Sclerosis; A Novel Finding
    Tse, Alexandra
    Finney-Stable, Antara
    Lin, Jerry
    Sadiq, Saud
    NEUROLOGY, 2018, 90
  • [43] Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity
    Drulovic, J
    Dujmovic, I
    Mesaros, S
    Samardzic, T
    Maksimovic, D
    Stojsavljevic, N
    Levic, Z
    Stojkovic, MM
    MULTIPLE SCLEROSIS JOURNAL, 2001, 7 (01) : 19 - 22
  • [44] MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression
    Martinez, Bridget
    Peplow, Philip, V
    NEURAL REGENERATION RESEARCH, 2020, 15 (04) : 606 - 619
  • [45] Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients
    Ménard, A
    Pierig, R
    Pelletier, J
    Bensa, P
    Belliveau, J
    Mandrand, B
    Perron, H
    Rieger, F
    NEUROSCIENCE LETTERS, 1998, 245 (01) : 49 - 52
  • [46] MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression
    Bridget Martinez
    Philip V Peplow
    NeuralRegenerationResearch, 2020, 15 (04) : 606 - 619
  • [47] INCIDENCE OF ANTIBODIES IN CEREBROSPINAL FLUID OF PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA
    Villa, Andres M.
    Videla, Cristina
    Garcea, Orlando
    Carballal, Guadalupe
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2009, 67 (3B) : 900 - 901
  • [48] Single cell analysis of cerebrospinal fluid leukocytes in treated multiple sclerosis patients
    Heming, M.
    Lu, I.
    Schwab, N.
    Schafflick, D.
    Gross, C.
    Wiendl, H.
    zu Hoerste, G. Meyer
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 82 - 82
  • [49] Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis
    Fiorini, Michele
    Zanusso, Gianluigi
    Benedetti, Maria Donata
    Righetti, Pier Giorgio
    Monaco, Salvatore
    PROTEOMICS CLINICAL APPLICATIONS, 2007, 1 (09) : 963 - 971
  • [50] Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis
    Eleonora Virgilio
    Domizia Vecchio
    Ilaria Crespi
    Chiara Puricelli
    Paolo Barbero
    Giulia Galli
    Roberto Cantello
    Umberto Dianzani
    Cristoforo Comi
    Journal of Neurology, 2022, 269 : 3249 - 3257